Improving cellular therapy operations through pre-harvest measurement of peripheral CD34-positive cell counts in allogeneic stem cell harvest

Shuhei Kurosawa; Kyoko Haraguchi; Yunoka Honma; Fuyuko Kawai; Moemi Ishiwada; Ryoko Iimura; Rei Watanabe; Sayuri Ishibashi; Kae Sakuma; Kiyomi Narishima; Misako Nishimura; Takashi Toya; Hiroaki Shimizu; Yuho Najima; Takeshi Kobayashi; Noriko Doki; Yoshiki Okuyama

doi:10.1111/1744-9987.14202

Improving cellular therapy operations through pre-harvest measurement of peripheral CD34-positive cell counts in allogeneic stem cell harvest

Ther Apher Dial. 2024 Aug 27. doi: 10.1111/1744-9987.14202. Online ahead of print.

Authors

Shuhei Kurosawa¹, Kyoko Haraguchi¹, Yunoka Honma¹, Fuyuko Kawai¹, Moemi Ishiwada¹, Ryoko Iimura¹, Rei Watanabe¹, Sayuri Ishibashi¹, Kae Sakuma¹, Kiyomi Narishima¹, Misako Nishimura¹, Takashi Toya², Hiroaki Shimizu², Yuho Najima², Takeshi Kobayashi², Noriko Doki², Yoshiki Okuyama¹

Affiliations

¹ Division of Transfusion and Cell Therapy, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
² Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.

PMID: 39192547
DOI: 10.1111/1744-9987.14202

Abstract

Introduction: Previously, our institution measured peripheral blood CD34 cell counts both pre- and post-peripheral blood stem cell harvest (PBSCH), with both samples analyzed simultaneously post-PBSCH. Since 2021, we have measured pre-CD34 cell counts during PBSCH, adjusting the processed blood volume based on these results. We retrospectively evaluated how this change impacted cellular therapy.

Methods: Related healthy donors were included and divided into 1-day and 2-day harvest cohorts. Donors with CD34 cell counts measured post- and during PBSCH were categorized into the previous and current sub-cohorts, respectively.

Results: Regarding the 1-day cohort (n = 212), the current sub-cohort had a significantly shorter average harvest duration (151 [standard deviation, SD = 45.1] vs. 180 [SD = 27.8] minutes, respectively) and higher average infusion rates (87.6% [SD = 21.1] vs. 78.1% [SD = 25.7], respectively) than the previous sub-cohort.

Conclusion: Adjusting the processed blood volume based on pre-PBSCH CD34 cell counts measured during the harvest may reduce donor burden and enhance workflow efficiency.

Keywords: CD34‐positive cells; apheresis‐related adverse events; collection efficiency; peripheral blood stem cell harvest; peripheral blood stem cell transplantation.